SkinCure Oncology Secures Patent for Innovative Image-Guided Technology in Nonmelanoma Skin Cancer Treatment
SkinCure Oncology has not yet submitted its data to the FDA for marketing clearance, however once cleared, the new devices will use hybrid laser-generated confocal and photoacoustic imaging in a single fused volumetric image.
This article was originally published in Dermatology Times.
SkinCure Oncology recently announced that it has received a patent from the US Patent and Trademark Office for a new image-guided technology that will be the fourth generation of superficial radiation therapy (SRT) for the treatment of nonmelanoma skin cancer.
SkinCure Oncology has not yet submitted its data to the FDA for marketing clearance, however once cleared, the new devices will use hybrid laser-generated confocal and photoacoustic imaging in a single fused volumetric image.
SkinCure Oncology expects the new devices to help clinicians to better image nonmelanoma skin cancer and provide accurate treatments. Additional information on SkinCure Oncology’s latest technology, also named GentleBeam, will be on display at booth 3555 at the 2024 American Academy of Dermatology Annual Meeting in San Diego, held March 8-12.
"The new devices are being designed to treat nonmelanoma skin cancer faster and more accurately than ever before. If cleared by the FDA, they will provide voxel-based beam shaping and modulation capabilities and are expected to significantly enhance treatment planning for Mohs surgery as well,” said Kerwin Brandt, CEO of SkinCure Oncology, in the news release.
Brandt added, “Patient care is the number one priority at SkinCure Oncology. Today we are partnered with more than 500 dermatologists, Mohs surgeons, and other quality-focused practitioners around the nation, providing them with the technology, professional staffing, and other support services necessary to deliver a noninvasive cancer treatment that has been shown to be just as, or more effective than traditional Mohs surgery.
Our goal, however, is to steadily improve the outcome and the patient treatment experience itself. Our ability to deliver on these objectives is limited only by our imagination, and to that end, we have now achieved a major new medical milestone. We continue to change the face of skin cancer treatment globally through both our comprehensive model and soon through our emerging new technology."
According to the announcement, SkinCure Oncology has also provided its dermatology practice partners with the Sensus Healthcare SRT-100 Vision system that directs a painless calibrated dose of x-ray-type radiotherapy, precision-guided using high-frequency ultrasound imaging. Brandt noted that SkinCure Oncology has delivered approximately 320 SRT-100 Vision units, accounting for more than approximately 90% of all SRT-100 Vision units sold worldwide.
